Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells.

ABSTRACT:

Background

Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the mechanisms underlying drug resistance in MM is a focal point to improve MM treatment.

Methods

In the current study, we analyzed further the role of redox imbalance induction in melphalan-induced toxicity both in human myeloma cell lines (HMCLs) and primary myeloma cells from patients.

Results

We developed an in-vitro model of short-term resistance to high-dose melphalan and identified that pretreatment with physiological concentration of GSH protects HMCLs from melphalan-indu

SUBMITTER: Gourzones C 

PROVIDER: S-EPMC6521290 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature